Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
PYXS on Nasdaq
Shares outstanding
62,130,557
Price per share
$1.76
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
30,142,945
Total reported value
$34,668,818
% of total 13F portfolios
0%
Share change
-780,136
Value change
-$6,939,019
Number of holders
77
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sullivan Lara 11% +9.1% $7,844,727 +$955,040 7,543,007 +14% Lara Sullivan, M.D. 31 Mar 2025
Laurion Capital Management LP 7.7% $9,880,747 4,796,479 Laurion Capital Management LP 31 Dec 2025
GordonMD Global Investments LP 6.2% $5,330,289 3,834,740 GordonMD Global Investments LP 14 Jul 2025
INTEGRATED CORE STRATEGIES (US) LLC 4% -26% $2,587,602 -$698,942 2,488,079 -21% Millennium Management LLC 31 Mar 2025
BlackRock, Inc. 1.5% -68% $2,192,635 -$5,718,934 926,805 -72% BlackRock, Inc. 30 Jun 2025
MILLENNIUM MANAGEMENT LLC 1.3% -73% $1,497,185 -$4,985,888 818,134 -77% Millennium Management LLC 30 Sep 2025
Ridgeback Capital Investments L.P. 0.6% $373,600 359,231 Ridgeback Capital Investments L.P. 31 Dec 2024

As of 31 Dec 2025, 77 institutional investors reported holding 30,142,945 shares of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS). This represents 49% of the company’s total 62,130,557 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) together control 46% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Pfizer Inc 11% 7,032,770 0% 3.4% $8,087,685
Laurion Capital Management LP 7.7% 4,796,479 +32% 0.38% $5,515,951
GordonMD Global Investments LP 6.6% 4,121,870 0% 3.4% $4,740,151
VANGUARD GROUP INC 3.8% 2,335,768 +7.9% 0% $2,686,133
Palo Alto Investors LP 1.7% 1,037,421 0% 0.17% $1,193,034
683 Capital Management, LLC 1.4% 891,910 +70% 0.09% $1,025,697
JANE STREET GROUP, LLC 1.3% 786,010 +159% 0% $903,911
BlackRock, Inc. 1.3% 784,077 +15% 0% $901,689
MILLENNIUM MANAGEMENT LLC 1.2% 743,107 -8.9% 0% $854,573
RENAISSANCE TECHNOLOGIES LLC 1.2% 728,380 +26% 0% $837,637
Atle Fund Management AB 0.99% 617,245 0.23% $709,831
BANK OF AMERICA CORP /DE/ 0.95% 587,851 -4.6% 0% $676,029
GEODE CAPITAL MANAGEMENT, LLC 0.93% 577,211 +6% 0% $664,211
Longaeva Partners L.P. 0.81% 503,214 0% 0.07% $578,696
UBS Group AG 0.63% 392,766 +5.1% 0% $451,681
MARSHALL WACE, LLP 0.63% 389,764 0% $448,229
Decheng Capital LLC 0.53% 326,810 0% 0.05% $375,832
ExodusPoint Capital Management, LP 0.51% 317,769 0% $365,434
XTX Topco Ltd 0.47% 289,033 +1533% 0.01% $332,388
CITADEL ADVISORS LLC 0.39% 243,589 -28% 0% $280,127
STATE STREET CORP 0.39% 241,637 +20% 0% $277,883
Point72 Asset Management, L.P. 0.3% 188,136 0% $216,356
Graham Capital Management, L.P. 0.3% 183,942 0.01% $211,533
Bank of New York Mellon Corp 0.27% 165,044 0% 0% $189,800
Qube Research & Technologies Ltd 0.23% 145,813 +373% 0% $167,685

Institutional Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 30,142,945 $34,668,818 -$6,939,019 $1.15 77
2025 Q3 26,713,589 $59,287,871 +$123,860 $2.22 72
2025 Q2 27,457,764 $30,197,446 -$2,879,012 $1.10 74
2025 Q1 30,249,732 $29,641,653 -$2,654,672 $0.98 88
2024 Q4 31,554,509 $49,227,444 -$20,797,470 $1.56 97
2024 Q3 27,885,908 $103,378,553 -$998,440 $3.67 91
2024 Q2 28,117,599 $93,075,160 +$16,220,879 $3.31 78
2024 Q1 22,927,678 $97,671,130 +$61,948,310 $4.26 69
2023 Q4 8,795,542 $15,830,945 +$874,420 $1.80 50
2023 Q3 7,757,315 $15,436,473 -$3,354,663 $1.99 49
2023 Q2 9,605,170 $24,586,580 -$3,344,692 $2.56 46
2023 Q1 10,344,999 $41,482,052 -$20,570,227 $4.01 46
2022 Q4 19,762,209 $26,479,807 -$1,331,635 $1.34 31
2022 Q3 19,443,728 $38,301,000 -$1,468,358 $1.97 35
2022 Q2 20,034,321 $47,682,000 -$658,113 $2.38 37
2022 Q1 18,945,997 $76,067,000 -$5,559,229 $4.04 44
2021 Q4 18,338,628 $199,903,000 +$199,792,959 $10.97 51